GLP-1 Telehealth Access by U.S. State, 2026

Source population. All clinics in the GLP1 Clinics directory marked active and verified against the CMS National Provider Identifier (NPI) Registry. As of the generation date, the directory contains 9,695 active providers across 49 states.

Telehealth detection. A clinic is counted as offering telehealth if it has self-reported telehealth availability in its directory listing or via verified provider data. The directory does not differentiate between telehealth-only practices and hybrid practices that offer both telehealth and in-person care; both are counted as telehealth-enabled.

Insurance acceptance. Recorded as a binary self-reported field. Clinics that accept any form of insurance (commercial, Medicare, Medicaid, or specific plan networks) are counted as insurance-accepting. The dataset does not break out which specific plans each clinic accepts.

Medication availability. A clinic is counted as offering tirzepatide or semaglutide if its self-reported medication list includes that molecule. The dataset does not differentiate between branded (Zepbound, Mounjaro, Wegovy, Ozempic, Rybelsus) and compounded versions; this is a known limitation. Compounded availability shifted significantly after the FDA shortage list change in February 2026, which is not reflected in this snapshot.

Inclusion criteria. States with fewer than 10 active clinics are excluded. The dataset covers 49 states meeting this threshold.

Limitations. Self-reported clinic data may not reflect current operational reality. Telehealth share is meaningfully lower than the share of new GLP-1 patient starts in 2026, because telehealth-only programs handle a disproportionate share of new patients per provider. The dataset is a snapshot and is regenerated quarterly.